Ready To Get Started?
Contact us to discuss licensing therapeutic assets or initiating a discovery partnership.
Or call (215) 966-6061
SARS-COV-2 VARIANT REPORTER VIRUSES
The largest collection of SARS-CoV-2 variant pseudoviruses for vaccine and therapeutic antibody development
Neutralization patterns of antibodies or vaccines can be profiled using SARS-CoV-2 variant Reporter Virus Particles (RVPs)
RVPs enable rapid and safe neutralization assays in your BSL-2 lab
RVP variants enable rapid testing in line with FDA recommendations
- Vaccine developers should assess immunogenicity of modified vaccines against targeted variants using a neutralization assay with SARS-CoV-2 wildtype or pseudoviruses1
- Antibody developers should report the neutralization activity of their antibody against circulating variants2
1FDA: Emergency Use Authorization for Vaccines to Prevent COVID-19. May 2021.
2FDA: Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency. February 2021.
